Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

被引：0

作者：

Gumuzio, Juan

Calleja, Veronique

Miles, James

Sancehz-Magraner, Lissete

Aguirre, Fernando

机构：

来源：

MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-23-A124

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A124

引用

页数：2

共 50 条

[41] Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
Dimitrios Mathios
Jacob Ruzevick
Christopher M. Jackson
Haiying Xu
Sagar R. Shah
Janis M. Taube
Peter C. Burger
Edward F. McCarthy
Alfredo Quinones-Hinojosa
Drew M. Pardoll
Michael Lim
Journal of Neuro-Oncology, 2016, 128 : 183 - 183
[42] New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Villanueva, Nicolas
Bazhenova, Lyudmila
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
[43] PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Lotfinejad, Parisa
Kazemi, Tohid
Mokhtarzadeh, Ahad
Shanehbandi, Dariush
Niaragh, Farhad Jadidi
Safaei, Sahar
Asadi, Milad
Baradaran, Behzad
LIFE SCIENCES, 2020, 259
[44] Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
Yan, Huiyu
Jiang, Aimin
Huang, Yinong
Zhang, Jun
Yang, Wenguang
Zhang, Wei
Liu, Tianya
FRONTIERS IN IMMUNOLOGY, 2023, 14
[45] Relevance of host and tumor PD-L1 in PD-L1 pathway blockade
Kryczek, Ilona
Lin, Heng
Wei, Shuang
Green, Michael
Zou, Weiping
JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
[46] From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, Xuan
Bao, Yulin
Meng, Bi
Xu, Zijian
Li, Sijin
Wang, Xu
Hou, Rui
Ma, Wen
Liu, Dan
Zheng, Junnian
Shi, Ming
FRONTIERS IN IMMUNOLOGY, 2022, 13
[47] Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Niu, Mengke
Liu, Yiming
Yi, Ming
Jiao, Dechao
Wu, Kongming
FRONTIERS IN IMMUNOLOGY, 2022, 13
[48] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
Duruisseaux, Michael
Rouquette, Isabelle
Adam, Julien
Cortot, Alexis
Cazes, Aurelie
Gibault, Laure
Damotte, Diane
Lantuejoul, Sylvie
ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
[49] Comparison of PD-L1 Immunohistochemistry Assays and Response to PD-L1 Inhibitors
Dacic, S.
Ancevski, K.
Aberrbock, S.
Herbst, C.
Villaruz, L.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2115 - S2115
[50] PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Huang, Changsheng
Ren, Shengxiang
Chen, Yaqi
Liu, Anyi
Wu, Qi
Jiang, Tao
Lv, Panjing
Song, Da
Hu, Fuqing
Lan, Jingqing
Sun, Li
Zheng, Xue
Luo, Xuelai
Chu, Qian
Jia, Keyi
Li, Yan
Wang, Jun
Zou, Caicun
Hu, Junbo
Wang, Guihua
SCIENCE ADVANCES, 2023, 9 (21)

← 1 2 3 4 5 →

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment